Idarucizumab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | Dabigatran |
| Names | |
| Trade names | Praxbind |
| Other names | BI-655075 |
| Clinical data | |
| Main uses | Reversal of dabigatran[1] |
| Side effects | Headache, nausea, constipation[1] |
| Pregnancy category |
|
| Routes of use | Intravenous |
| Typical dose | 5 gram[1] |
| External links | |
| AHFS/Drugs.com | Monograph |
| Legal | |
| License data |
|
| Legal status | |
| Chemical and physical data | |
| Formula | C2131H3299N555O671S11 |
| Molar mass | 47782.71 g·mol−1 |
Idarucizumab, sold under the brand name Praxbind, is a medication used to reverse the effects of dabigatran.[1] Specifically it is used if severe bleeding or urgent surgery is required.[1] It is given by injection into a vein.[3]
Common side effects include headache, nausea, and constipation.[1] Severe side effects may include blood clots and allergic reactions.[1] It is a monoclonal antibody that works by binding to and inactivating dabigatran.[1][2]
Idarucizumab was approved for medical use in the United States and Europe in 2015.[1][2] In the United Kingdom it costs the NHS about £2,400 for a dose as of 2021.[3] This amount in the United States costs about 4,500 USD.[4]
Medical uses
Dabigatran can be started again once 24 hours has passed from this medication being given.[3]
Dosage
It is given as a dose of 5 gram.[1] Occasionally a second 5 gram dose may be used.[3]
Society and culture
Names
Idarucizumab is the International nonproprietary name (INN).[5] The description was updated in 2016.[6] Idarucizumab is the United States Adopted Name (USAN).[7]
See also
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 "Praxbind- idarucizumab injection". DailyMed. 1 December 2019. Archived from the original on 25 March 2021. Retrieved 19 August 2020.
- ↑ 2.0 2.1 2.2 "Praxbind EPAR". European Medicines Agency (EMA). Archived from the original on 25 October 2020. Retrieved 16 October 2020.
- ↑ 3.0 3.1 3.2 3.3 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 131. ISBN 978-0857114105.
- ↑ "Praxbind Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 2 May 2021. Retrieved 25 November 2021.
- ↑ World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1): 90–91. hdl:10665/331151.
- ↑ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76". WHO Drug Information. 30 (3): 544. hdl:10665/331020.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab Archived 2015-06-27 at the Wayback Machine, American Medical Association.
External links
| External sites: | |
|---|---|
| Identifiers: |
|
 | This monoclonal antibody–related article is a stub. You can help MDWiki by expanding it. |
- Pages using duplicate arguments in template calls
- Webarchive template wayback links
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Chemicals that do not have a ChemSpider ID assigned
- Antidotes
- Monoclonal antibodies
- Boehringer Ingelheim
- All stub articles
- Monoclonal antibody stubs